SCYNEXIS Inc
Company Profile
Business description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Contact
1 Evertrust Plaza
13th Floor
Jersey CityNJ07302 - 6548
USAT: +1 201 884-5485
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
29
Stocks News & Analysis
stocks
Are small caps finally back?
stocks
Chart of the Week: Modest earnings growth at odds with overvalued bank shares
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,329.10 | 50.90 | 0.55% |
CAC 40 | 8,243.87 | 37.00 | 0.45% |
DAX 40 | 24,112.30 | 38.83 | -0.16% |
Dow JONES (US) | 46,590.41 | 334.33 | -0.71% |
FTSE 100 | 9,530.66 | 15.66 | 0.16% |
HKSE | 25,936.00 | 154.23 | 0.60% |
NASDAQ | 22,740.40 | 213.27 | -0.93% |
Nikkei 225 | 48,641.61 | 666.18 | -1.35% |
NZX 50 Index | 13,377.10 | 70.66 | 0.53% |
S&P 500 | 6,699.40 | 35.95 | -0.53% |
S&P/ASX 200 | 9,032.80 | 46.60 | 0.52% |
SSE Composite Index | 3,922.41 | 8.65 | 0.22% |